Evidence map›Paper›PMID 25695618›Full record

Trial reportJournal of hypertension2015

TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives.

Martina Chittani, Roberta Zaninello, Chiara Lanzani, Francesca Frau, Maria F Ortu, Erika Salvi, Giovanni Fresu, Lorena Citterio, Daniele Braga, Daniela A Piras and 26 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Pharmacogenomics of Hypertension Treatment.International journal of molecular sciences · 2020
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Is There a Role for Genomics in the Management of Hypertension?International journal of molecular sciences · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors at 14 institutions in 5 countries.

Martina ChittaniaDepartment of Health Sciences, University of Milan at San Paolo Hospital, and Filarete Foundation, Genomic and Bioinformatics Unit, Milan bHypertension and Related Disease Centre, AOU-University of Sassari, Sassari cUniversità Vita Salute San Raffaele, Nephrology and Dialysis and Hypertension Unit, San Raffaele Scientific Institute, Milan, Italy dDepartment of Medicine, University of Helsinki and Helsinki University Central Hospital eInstitute for Molecular Medicine Finland FIMM, University of Helsinki, Helsinki, Finland fDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota gHuman Genetics and Institute of Molecular Medicine, University of Texas Health Science Center, Houston, Texas hRenal Division, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA iInstitute of Cardiovascular and Medical Sciences, College of Medicine Veterinary and Life Sciences, University of Glasgow, Glasgow, UK jDepartment of Clinical Sciences, Lund University, Malmö, Sweden kDepartment of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, College of Pharmacy, University of Florida, Gainesville, Florida, USA lRespiratory Medicine Unit, Department of Medicine and CMM, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden mDepartment of Medical Biotechnologies and Translational Medicine, University of Milan, and Humanitas Clinical and Research Center, University of Milan, and National Research Council of Italy, Rozzano (MI) nDepartment of Clinical Medicine, Cardiovascular and Immunological Sciences, University of Naples 'Federico II', Naples, Italy *Martina Chittani and Roberta Zaninello contributed equally to the writing of this article.
Roberta Zaninello
Chiara Lanzani
Francesca Frau
Maria F Ortu
Erika Salvi
Giovanni Fresu
Lorena Citterio
Daniele Braga
Daniela A Piras
Simona Delli Carpini
Dinesh Velayutham
Marco Simonini
Giuseppe Argiolas
Simona Pozzoli
Chiara Troffa
Valeria Glorioso
Kimmo K Kontula
Timo P Hiltunen
Kati M Donner
Stephen T Turner
Eric Boerwinkle
Arlene B Chapman
Sandosh Padmanabhan
Anna F Dominiczak
Olle Melander
Julie A Johnson
Rhonda M Cooper-Dehoff
Yan Gong
Natalia V Rivera
Gianluigi Condorelli
Bruno Trimarco
Paolo Manunta
Daniele Cusi
Nicola Glorioso
Cristina Barlassina
University of Sassari · ITVita-Salute San Raffaele University · ITFondazione Filarete · ITUniversity of Milan · ITUniversity of Glasgow · GBUniversity of Helsinki · FIEmory University · USHelsinki University Hospital · FIKarolinska University Hospital · SELund University · SEMayo Clinic · USNational Research Council · ITThe University of Texas Health Science Center at Houston · USUniversity of Naples Federico II · IT

Funding

Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
NIGMS NIH HHS U01 GM074492
6 · The paper itself

Abstract

backgroundThiazide diuretics have been recommended as a first-line antihypertensive treatment, although the choice of 'the right drug in the individual essential hypertensive patient' remains still empirical. Essential hypertension is a complex, polygenic disease derived from the interaction of patient's genetic background with the environment. Pharmacogenomics could be a useful tool to pinpoint gene variants involved in antihypertensive drug response, thus optimizing therapeutic advantages and minimizing side effects. METHODS AND

resultsWe looked for variants associated with blood pressure response to hydrochlorothiazide over an 8-week follow-up by means of a genome-wide association analysis in two Italian cohorts of never-treated essential hypertensive patients: 343 samples from Sardinia and 142 from Milan. TET2 and CSMD1 as plausible candidate genes to affect SBP response to hydrochlorothiazide were identified. The specificity of our findings for hydrochlorothiazide was confirmed in an independent cohort of essential hypertensive patients treated with losartan. Our best findings were also tested for replication in four independent hypertensive samples of European Ancestry, such as GENetics of drug RESponsiveness in essential hypertension, Genetic Epidemiology of Responses to Antihypertensives, NORdic DILtiazem intervention, Pharmacogenomics Evaluation of Antihypertensive Responses, and Campania Salute Network-StayOnDiur. We validated a polymorphism in CSMD1 and UGGT2.

conclusionThis exploratory study reports two plausible loci associated with SBP response to hydrochlorothiazide: TET2, an aldosterone-responsive mediator of αENaC gene transcription; and CSMD1, previously described as associated with hypertension in a case-control study.

Indexed as

AdultAgedAldosteroneAntihypertensive AgentsBlood PressureCase-Control StudiesDioxygenasesDNA-Binding ProteinsEssential HypertensionGenome-Wide Association StudyHumansHydrochlorothiazideHypertensionItalyLosartanMaleAldosteroneAntihypertensive AgentsCSMD1 protein, humanDioxygenasesDNA-Binding ProteinsHydrochlorothiazideLosartanMembrane ProteinsProto-Oncogene ProteinsSodium Chloride Symporter InhibitorsTET2 protein, humanTumor Suppressor Proteins

Identifiers

PMID25695618
PMCPMC4484731
OpenAlexW2008226844

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.